Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL) plans to submit a U.S. FDA‑aligned NDA for AXPAXLI™ in wet AMD in 4Q 2026. The filing will rely on SOL‑1 Week 52 efficacy and safety plus interim SOL‑R safety to exceed 300 treated patients, using the 505(b)(2) pathway.
SOL‑R efficacy data will not be in the NDA; the trial will remain masked to Week 96 to assess new secondary endpoints versus aflibercept, with topline results expected in 1Q 2028. The company will also prioritize a single global Phase 3 DR trial, HELIOS‑3, evaluating once‑yearly AXPAXLI.
Ocular Therapeutix (NASDAQ: OCUL) granted Nasdaq Rule 5635(c)(4) inducement equity awards to seven new non-executive employees under its 2019 Inducement Stock Incentive Plan.
The June 1, 2026 grants include options for 51,775 shares at $8.93 and 16,950 RSUs with multi‑year vesting.
Ocular Therapeutix (NASDAQ:OCUL) will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026. Company leaders and external experts will join fireside chats and panels focused on OTX-TKI and retinal diseases.
Multiple sessions will cover efficacy, safety, and program updates.
Ocular Therapeutix (NASDAQ:OCUL) will host an Investor Day in New York City on June 17, 2026, starting at 2:00 PM ET, with in-person and virtual access.
The event will feature updates on AXPAXLI wet AMD NDA plans, SOL-R and SOL-X trials, and a registrational diabetic retinopathy program.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Head of HR, Amy Ricca, under its 2019 Inducement Stock Incentive Plan and Nasdaq Rule 5635(c)(4).
The grants include options for 75,000 shares at $9.28 and 25,000 restricted stock units with multi-year vesting schedules.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to twelve newly hired non-executive employees effective May 4, 2026 under its 2019 Inducement Stock Incentive Plan pursuant to Nasdaq Rule 5635(c)(4).
The awards include non-statutory stock options to purchase an aggregate of 127,650 shares and restricted stock units totaling 41,550 shares; option exercise price is $9.71 per share, equal to the closing market price on the grant date. Options have a ten-year term and vest over four years; RSUs vest in three equal annual installments.
Ocular Therapeutix (NASDAQ: OCUL) reported Q1 2026 results and program milestones on May 5, 2026. Key clinical highlights include positive Phase 3 SOL-1 superiority results for AXPAXLI in wet AMD (p=0.0006) and initiation of the SOL-X extension. Cash was $666.7 million as of March 31, 2026, with expected runway into 2028.
The company plans an NDA submission for AXPAXLI based on SOL-1 Week 52 data, subject to FDA discussions, and will host Investor Day on June 17, 2026.
Ocular Therapeutix (NASDAQ: OCUL) announced enrollment of the first patient in SOL-X, a three-year open-label long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration (wet AMD).
SOL-X invites subjects who completed two-year follow-up in SOL-1 or SOL-R to assess long-term safety, sustained VEGF suppression, reduced treatment burden, and potential to improve long-term visual outcomes.
Ocular Therapeutix (NASDAQ: OCUL) will report first-quarter 2026 financial results and host a live conference call and webcast on May 5, 2026 at 8:00 AM ET. The company will discuss business progress and results for the quarter ended March 31, 2026. A replay will be archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific and investor conferences in May 2026, including Bank of America Health Care Conference (May 12), Stifel Virtual Ophthalmology Forum (May 26), ARVO (May 1–7) and Retina World Congress (May 14–17), plus the Royal College of Ophthalmologists congress (May 18–20).
Key presentations cover Phase 3 OTX-TKI SOL-1 results, TKI program updates, real-world anti-VEGF analyses, and company fireside chats. Webcasts will be available via the company investor relations Events and Presentations page, with replays archived for at least 30 days.